Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 430
interventional 413
Observational 15
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 198
Drug|Other 44
Biological|Drug 30
Biological|Drug|Other 20
Biological 15
Biological|Other 11
Drug|Other|Procedure|Radiation 11
Drug|Procedure 11
Biological|Drug|Procedure|Radiation 9
Biological|Drug|Procedure 7
Biological|Other|Procedure 6
Biological|Drug|Other|Procedure 5
Biological|Drug|Other|Procedure|Radiation 5
Biological|Drug|Radiation 5
Drug|Procedure|Radiation 5
Drug|Other|Procedure 4
Drug|placebo 4
Drug|Genetic|Other 3
Drug|Radiation 3
Biological|Drug|Genetic|Other 2
Biological|Drug|Genetic|Other|Procedure 2
Other 2
Other|Procedure 2
Biological|Drug|Other|Radiation 1
Biological|Procedure|Radiation 1
Combination Product 1
Dietary Supplement|Other 1
Drug|Genetic 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo|Procedure 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 278
China 10
United States|Canada 10
France 8
Italy 6
NA 6
Canada 5
Germany 4
Japan 4
Spain 4
United States|Germany|Italy 4
United States|Italy 4
United States|United Kingdom 4
Australia 2
Australia|United Kingdom 2
Denmark|Finland|Norway|Sweden 2
Korea, Republic of 2
Switzerland 2
United Kingdom 2
United States|Denmark|Germany 2
Australia|France|Germany|Netherlands 1
Austria|Switzerland 1
Belgium|Brazil|Canada|Chile|Colombia|Czechia|France|Germany|Hungary|Ireland|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Ukraine|United Kingdom 1
Belgium|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Belgium|France 1
Belgium|France|Germany|Netherlands|Poland|Portugal|Spain 1
Denmark|Germany|Italy|Norway|Sweden 1
Denmark|Netherlands|Spain|United Kingdom 1
France|Germany 1
France|Italy|Switzerland 1
France|United Kingdom 1
France|United States|Belgium|Czechia|Denmark|Germany|Israel|Italy|Poland|Spain|United Kingdom 1
Germany|Italy|Switzerland 1
Hong Kong 1
Hungary 1
India 1
Italy|Poland|United Kingdom 1
Japan|Korea, Republic of 1
Japan|United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Peru|Poland|Russian Federation|Spain|Taiwan|Ukraine|Vietnam 1
New Zealand 1
Norway 1
Poland 1
Spain|Slovakia|United States|Argentina|Australia|Belgium|Brazil|Canada|China|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Puerto Rico|Russian Federation|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
Sweden|Denmark|Finland|Norway 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|France|Germany|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|China|France|New Zealand|Poland|Spain|Taiwan 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Spain|Turkey|Ukraine|United Kingdom 1
United States|Australia|Brazil|Canada|Mexico|New Zealand|Peru 1
United States|Australia|Canada 1
United States|Australia|Czechia|France|Germany|Italy|Korea, Republic of|Poland|Romania|Russian Federation|Serbia 1
United States|Australia|France|Poland 1
United States|Australia|Israel|Italy|Korea, Republic of|Poland|Slovakia|Spain|United Kingdom 1
United States|Australia|Peru|Puerto Rico|South Africa 1
United States|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Czechia|Germany|Hungary|India|Israel|Italy|Malaysia|Morocco|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|South Africa|Spain|Taiwan|Thailand|Tunisia|Turkey|Ukraine 1
United States|Austria|Belgium|Colombia|France|Germany|Hungary|Israel|Italy|Puerto Rico|Singapore|Spain|Turkey|United Kingdom 1
United States|Austria|France|Germany 1
United States|Belgium|Canada|Germany|Korea, Republic of 1
United States|Belgium|France|Germany|Italy|Korea, Republic of|Spain|Turkey 1
United States|Belgium|France|Israel|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Belgium|France|Italy 1
United States|Denmark 1
United States|France|Germany|Netherlands 1
United States|France|United Kingdom 1
United States|Germany|Poland|United Kingdom 1
United States|Germany|Puerto Rico 1
United States|Italy|Poland 1
United States|Italy|Spain|United Kingdom 1
United States|Italy|United Kingdom 1
United States|Puerto Rico 1
United States|Spain 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 190
2 35
3 17
4 11
5 16
6 11
7 12
8 4
9 4
10 10
11 14
12 5
13 3
14 4
15 3
16 5
17 7
18 2
19 3
20 5
21 2
22 1
23 1
25 4
28 1
30 2
31 3
32 1
35 1
37 1
40 1
42 1
43 2
48 3
56 1
57 1
67 1
70 1
72 1
81 1
82 1
87 1
97 1
98 1
112 1
113 1
114 1
128 1
134 1
140 1
144 1
147 1
150 2
164 1
195 1
203 1
204 1
241 1
319 1
393 1
418 1

Phase

Phase Study_Count
Phase 2 182
Phase 1 110
Phase 1/Phase 2 73
Phase 3 23
N/A 12
Early Phase 1 9
Phase 2/Phase 3 2
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 288
2 64
3 23
4 9
5 3
7 2
8 2
10 2
11 1
NA 19

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 7.00000 2.00000 2.00000 1.00000 4.00000 370.0 54.0000 75.0
1st Qu. 10.00000 7.50000 20.00000 30.00000 30.00000 502.5 235.0000 81.5
Median 16.00000 45.50000 34.00000 45.00000 49.50000 635.0 447.0000 88.0
Mean 20.66667 67.41667 53.98182 66.58904 63.28652 635.0 470.5652 88.0
3rd Qu. 30.00000 100.00000 60.00000 96.00000 72.75000 767.5 584.5000 94.5
Max. 50.00000 200.00000 314.00000 403.00000 373.00000 900.0 1337.0000 101.0

Trial Group Type

group_type Group_Count
Experimental 556
Active Comparator 27
NA 19
Other 7
Placebo Comparator 4
No Intervention 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 309
Parallel Assignment 78
Sequential Assignment 19
NA 6
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 395
Supportive Care 11
Prevention 3
Basic Science 2
Other 2

Observational Studies

Studies by Country

Country Study_Count
United States 3
France 2
Spain 2
Austria|France|Germany|Greece|Italy|Netherlands|Spain 1
China 1
Germany 1
India 1
Korea, Republic of 1
NA 1
United States|Australia|Canada|Puerto Rico 1
United States|Germany|Italy|United Kingdom 1

Sites per Study

Site_count Study_Count
1 7
8 1
9 1
14 1
16 1
43 1
54 1
75 1
130 1

Enrollment Metrics

Measure Observational
Min 25.0000
1st Qu 57.0000
Median 105.0000
Mean 271.1333
3rd Qu 246.5000
Max 1600.0000

Observation Model

observational_model Study_Count
Cohort 9
Case-Only 5
NA 1

Time Perspective

time_perspective Study_Count
Prospective 7
Retrospective 7
NA 1

Registries

Studies by Country

Country Study_Count
France 1
Korea, Republic of 1

Sites per Study

Site_count Study_Count
2 1
7 1

Enrollment Metrics

Measure Registries
Min 40
1st Qu 1530
Median 3020
Mean 3020
3rd Qu 4510
Max 6000

Registry Model

observational_model Study_Count
Case-Only 1
Cohort 1

Time Perspective

time_perspective Study_Count
Other 1
Prospective 1

Follow-up

target_duration Study_Count
1 Year 1
9 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03410901 TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03410901 Recruiting Stanford University 2020-10-09
NCT03323151 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03323151 Recruiting PrECOG, LLC. 2024-01-31
NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders https://ClinicalTrials.gov/show/NCT03314974 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-10
NCT03311126 Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03311126 Recruiting University of Wisconsin, Madison 2024-05-15
NCT03295240 The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03295240 Recruiting Memorial Sloan Kettering Cancer Center 2021-09-20
NCT03282396 Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03282396 Recruiting M.D. Anderson Cancer Center 2022-02-28
NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03277729 Recruiting Fred Hutchinson Cancer Research Center 2022-11-16
NCT03267433 Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission https://ClinicalTrials.gov/show/NCT03267433 Recruiting Eastern Cooperative Oncology Group 2027-01-31
NCT03246906 Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation https://ClinicalTrials.gov/show/NCT03246906 Recruiting Fred Hutchinson Cancer Research Center 2022-08-15
NCT03235544 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) https://ClinicalTrials.gov/show/NCT03235544 Recruiting Incyte Corporation 2020-07-31
NCT03229382 Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell https://ClinicalTrials.gov/show/NCT03229382 Recruiting Polish Lymphoma Research Group 2023-07-31
NCT03219047 Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03219047 Recruiting M.D. Anderson Cancer Center 2020-09-30
NCT03206970 Study of Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT03206970 Active, not recruiting BeiGene 2019-02-15
NCT03190330 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion https://ClinicalTrials.gov/show/NCT03190330 Recruiting Johnson & Johnson Private Limited 2021-09-29
NCT03162536 A Study of ARQ 531 in Patients With Selected Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03162536 Recruiting ArQule 2021-12-31
NCT03153202 Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT03153202 Recruiting Icahn School of Medicine at Mount Sinai 2021-04-10
NCT03151057 Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies https://ClinicalTrials.gov/show/NCT03151057 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2020-09-30
NCT03128359 High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03128359 Recruiting City of Hope Medical Center 2021-01-31
NCT03097770 Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 https://ClinicalTrials.gov/show/NCT03097770 Recruiting Chinese PLA General Hospital 2019-05-10
NCT03037645 Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers https://ClinicalTrials.gov/show/NCT03037645 Recruiting Sunesis Pharmaceuticals 2020-12-31
NCT03035331 Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03035331 Recruiting Mayo Clinic 2021-02-15
NCT03028103 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients https://ClinicalTrials.gov/show/NCT03028103 Active, not recruiting Epizyme, Inc. 2019-10-31
NCT03019666 Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL https://ClinicalTrials.gov/show/NCT03019666 Recruiting Masonic Cancer Center, University of Minnesota 2020-09-30
NCT03019640 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03019640 Recruiting M.D. Anderson Cancer Center 2020-03-31
NCT03015896 Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03015896 Recruiting Ohio State University Comprehensive Cancer Center 2020-04-30
NCT03010982 Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors https://ClinicalTrials.gov/show/NCT03010982 Completed Epizyme, Inc. 2019-01-08
NCT03010358 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03010358 Active, not recruiting OHSU Knight Cancer Institute 2022-02-28
NCT02996773 Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine https://ClinicalTrials.gov/show/NCT02996773 Recruiting University of Arizona 2022-11-29
NCT02991638 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers https://ClinicalTrials.gov/show/NCT02991638 Recruiting The University of Hong Kong 2020-12-31
NCT02972840 A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02972840 Recruiting Acerta Pharma BV 2022-10-31
NCT02952508 Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) https://ClinicalTrials.gov/show/NCT02952508 Recruiting Cellectar Biosciences, Inc. 2020-07-31
NCT02950220 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02950220 Completed Ohio State University Comprehensive Cancer Center 2018-11-19
NCT02914938 A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02914938 Recruiting MEI Pharma, Inc. 2021-09-30
NCT02896582 Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance https://ClinicalTrials.gov/show/NCT02896582 Active, not recruiting The Lymphoma Academic Research Organisation 2019-03-31
NCT02869633 Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02869633 Active, not recruiting Vanderbilt-Ingram Cancer Center 2021-10-31
NCT02858258 ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02858258 Recruiting European Mantle Cell Lymphoma Network 2021-05-31
NCT02825836 BTK Inhibitor in B Cell Malignancies https://ClinicalTrials.gov/show/NCT02825836 Active, not recruiting EMD Serono 2021-09-01
NCT02797470 Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant https://ClinicalTrials.gov/show/NCT02797470 Recruiting AIDS Malignancy Consortium 2021-09-30
NCT02756247 A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma https://ClinicalTrials.gov/show/NCT02756247 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT02745769 A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents https://ClinicalTrials.gov/show/NCT02745769 Completed Eli Lilly and Company 2018-11-05
NCT02736617 Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02736617 Recruiting OHSU Knight Cancer Institute 2022-12-01
NCT02728531 Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02728531 Active, not recruiting Washington University School of Medicine 2019-01-16
NCT02722668 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep https://ClinicalTrials.gov/show/NCT02722668 Recruiting Masonic Cancer Center, University of Minnesota 2028-05-31
NCT02717624 A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL https://ClinicalTrials.gov/show/NCT02717624 Recruiting Acerta Pharma BV 2026-05-31
NCT02682641 Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL https://ClinicalTrials.gov/show/NCT02682641 Active, not recruiting Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2019-12-31
NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) https://ClinicalTrials.gov/show/NCT02669017 Completed ADC Therapeutics S.A. 2019-02-21
NCT02661035 Allo HSCT Using RIC for Hematological Diseases https://ClinicalTrials.gov/show/NCT02661035 Recruiting Masonic Cancer Center, University of Minnesota 2023-03-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02650999 Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas https://ClinicalTrials.gov/show/NCT02650999 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2019-02-25
NCT02633137 Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02633137 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT02632396 Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission https://ClinicalTrials.gov/show/NCT02632396 Recruiting Emory University 2021-04-30
NCT02631044 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) https://ClinicalTrials.gov/show/NCT02631044 Recruiting Juno Therapeutics, a Subsidiary of Celgene 2022-12-31
NCT02603445 Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL https://ClinicalTrials.gov/show/NCT02603445 Completed Novartis 2018-07-10
NCT01028716 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01028716 Recruiting Fred Hutchinson Cancer Research Center 2024-01-04
NCT03112174 Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) https://ClinicalTrials.gov/show/NCT03112174 Recruiting Pharmacyclics LLC. 2022-03-31
NCT03088878 A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT03088878 Recruiting University of California, San Diego 2020-10-01
NCT02927964 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02927964 Recruiting Stanford University 2021-11-30
NCT02793583 Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma https://ClinicalTrials.gov/show/NCT02793583 Recruiting TG Therapeutics, Inc. 2021-05-31
NCT02572453 Testing AT13387 (Onalespib) in Patients With Relapsed/Refractory ALK+ Anaplastic Large Cell Lymphoma (ALCL), Mantle Cell Lymphoma (MCL), and BCL6+ Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02572453 Active, not recruiting National Cancer Institute (NCI) 2020-10-01
NCT04116437 Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment https://ClinicalTrials.gov/show/NCT04116437 Recruiting BeiGene 2022-09-30
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02568553 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT00101101 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00101101 Active, not recruiting H. Lee Moffitt Cancer Center and Research Institute 2012-10-31
NCT00005780 Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00005780 Active, not recruiting National Institutes of Health Clinical Center (CC) 2005-08-31
NCT02558816 A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT02558816 Active, not recruiting Nantes University Hospital 2019-04-30
NCT01381692 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01381692 Active, not recruiting National Cancer Institute (NCI) 2014-07-23
NCT02507336 Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 https://ClinicalTrials.gov/show/NCT02507336 Active, not recruiting University of Miami 2020-11-30
NCT02494700 Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02494700 Recruiting M.D. Anderson Cancer Center 2021-10-31
NCT02489123 Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02489123 Active, not recruiting University of Washington 2023-07-01
NCT02483000 Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies https://ClinicalTrials.gov/show/NCT02483000 Active, not recruiting Fred Hutchinson Cancer Research Center 2019-11-17
NCT02460276 A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02460276 Completed Lund University Hospital 2019-12-31
NCT02446236 Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02446236 Active, not recruiting Hackensack Meridian Health 2022-12-31
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02427620 Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02427620 Active, not recruiting M.D. Anderson Cancer Center 2021-06-30
NCT02420795 Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02420795 Recruiting M.D. Anderson Cancer Center 2021-11-01
NCT02356458 Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02356458 Active, not recruiting Swiss Group for Clinical Cancer Research 2021-03-31
NCT02339922 Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02339922 Active, not recruiting University of Washington 2025-01-06
NCT02278796 A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) https://ClinicalTrials.gov/show/NCT02278796 Active, not recruiting University Hospital Inselspital, Berne 2018-11-28
NCT02268851 A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL https://ClinicalTrials.gov/show/NCT02268851 Active, not recruiting Dana-Farber Cancer Institute 2018-05-31
NCT02267915 Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT https://ClinicalTrials.gov/show/NCT02267915 Active, not recruiting Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2019-12-31
NCT02257242 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02257242 Recruiting Brown University 2020-12-31
NCT02242097 Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02242097 Active, not recruiting Northwestern University 2022-06-30
NCT02240719 Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer https://ClinicalTrials.gov/show/NCT02240719 Completed University of California, Davis 2018-04-09
NCT02216890 Safety Study of SGN-CD70A in Cancer Patients https://ClinicalTrials.gov/show/NCT02216890 Completed Seattle Genetics, Inc. 2017-02-15
NCT02213926 An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02213926 Active, not recruiting Acerta Pharma BV 2017-02-28
NCT02213913 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02213913 Recruiting University of Chicago 2020-07-29
NCT02169180 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02169180 Completed Janssen Pharmaceutical K.K. 2016-11-30
NCT02159755 Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02159755 Active, not recruiting National Cancer Institute (NCI) 2018-06-25
NCT02153580 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02153580 Recruiting City of Hope Medical Center 2021-12-31
NCT02142530 Carfilzomib Plus Belinostat in Relapsed/Refractory NHL https://ClinicalTrials.gov/show/NCT02142530 Completed Massachusetts General Hospital 2017-03-31
NCT01318317 Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01318317 Active, not recruiting City of Hope Medical Center 2022-08-31
NCT01314014 Imexon for Relapsed Follicular and Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT01314014 Completed University of Rochester 2013-03-31
NCT01300026 AMG 319 Lymphoid Malignancy FIH https://ClinicalTrials.gov/show/NCT01300026 Completed Amgen 2013-10-31
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02051257 Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02051257 Active, not recruiting City of Hope Medical Center 2021-06-30
NCT02049541 Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02049541 Active, not recruiting Ohio State University Comprehensive Cancer Center 2018-09-12
NCT03932331 Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies https://ClinicalTrials.gov/show/NCT03932331 Recruiting AstraZeneca 2022-03-25
NCT00088205 Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00088205 Completed Eli Lilly and Company 2008-05-31
NCT04234061 Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04234061 Recruiting Peter MacCallum Cancer Centre, Australia 2027-09-01
NCT03479268 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03479268 Recruiting City of Hope Medical Center 2022-04-01
NCT03329950 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT03329950 Recruiting Celldex Therapeutics 2021-08-31
NCT02013128 Ublituximab + Ibrutinib in Select B-cell Malignancies https://ClinicalTrials.gov/show/NCT02013128 Completed TG Therapeutics, Inc. 2015-12-31
NCT01996865 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. https://ClinicalTrials.gov/show/NCT01996865 Active, not recruiting Celgene 2023-04-08
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01955499 Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01955499 Active, not recruiting National Cancer Institute (NCI) 2021-12-31
NCT01921387 Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01921387 Active, not recruiting Fred Hutchinson Cancer Research Center 2017-07-26
NCT01897012 Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas https://ClinicalTrials.gov/show/NCT01897012 Completed National Cancer Institute (NCI) 2018-10-31
NCT01880567 Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01880567 Recruiting M.D. Anderson Cancer Center 2020-07-31
NCT01865617 Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT01865617 Active, not recruiting Fred Hutchinson Cancer Research Center 2034-04-02
NCT01865110 R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL https://ClinicalTrials.gov/show/NCT01865110 Active, not recruiting The Lymphoma Academic Research Organisation 2021-06-30
NCT01851551 Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL https://ClinicalTrials.gov/show/NCT01851551 Completed Acrotech Biopharma LLC 2004-04-30
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01838434 Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01838434 Completed Alliance for Clinical Trials in Oncology 2014-09-30
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01815749 Active, not recruiting City of Hope Medical Center 2020-10-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) https://ClinicalTrials.gov/show/NCT01804686 Enrolling by invitation Janssen Research & Development, LLC 2026-12-31
NCT01799889 Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01799889 Completed Gilead Sciences 2017-09-14
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01786135 A Safety Study of SGN-CD19A for B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01786135 Completed Seattle Genetics, Inc. 2015-08-31
NCT01776840 A Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01776840 Active, not recruiting Janssen Research & Development, LLC 2021-06-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01744912 Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01744912 Completed TG Therapeutics, Inc. 2014-05-31
NCT01739309 Study of LY2835219 for Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01739309 Active, not recruiting Eli Lilly and Company 2015-09-28
NCT01737177 Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL https://ClinicalTrials.gov/show/NCT01737177 Completed Fondazione Italiana Linfomi ONLUS 2014-07-31
NCT01719250 Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01719250 Completed Mayo Clinic 2016-09-16
NCT01718691 Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01718691 Completed SymBio Pharmaceuticals 2013-11-30
NCT01695941 Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01695941 Active, not recruiting National Cancer Institute (NCI) 2018-05-29
NCT01693614 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL https://ClinicalTrials.gov/show/NCT01693614 Completed Novartis 2017-07-21
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01665768 Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma https://ClinicalTrials.gov/show/NCT01665768 Active, not recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2017-10-31
NCT01662050 Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL https://ClinicalTrials.gov/show/NCT01662050 Completed Fondazione Italiana Linfomi ONLUS 2012-08-31
NCT01661881 Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01661881 Active, not recruiting Dana-Farber Cancer Institute 2015-02-28
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01652144 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01652144 Completed Canadian Cancer Trials Group 2014-12-02
NCT01646021 Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy https://ClinicalTrials.gov/show/NCT01646021 Completed Janssen Research & Development, LLC 2015-06-05
NCT01599949 A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy https://ClinicalTrials.gov/show/NCT01599949 Completed Janssen Research & Development, LLC 2015-05-31
NCT01597778 Double Cord Versus Haploidentical (BMT CTN 1101) https://ClinicalTrials.gov/show/NCT01597778 Active, not recruiting Medical College of Wisconsin 2020-06-30
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01562977 Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL https://ClinicalTrials.gov/show/NCT01562977 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2015-04-30
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01527149 Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01527149 Active, not recruiting Roswell Park Cancer Institute 2018-04-26
NCT01527045 Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01527045 Completed Fred Hutchinson Cancer Research Center 2018-10-31
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01504776 Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT01504776 Completed Augusta University 2014-09-30
NCT01484093 Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01484093 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01479842 Active, not recruiting Ohio State University Comprehensive Cancer Center 2014-03-31
NCT01475058 CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant https://ClinicalTrials.gov/show/NCT01475058 Completed Fred Hutchinson Cancer Research Center 2014-04-30
NCT01472562 Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01472562 Active, not recruiting Weill Medical College of Cornell University 2014-04-30
NCT01460134 A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers https://ClinicalTrials.gov/show/NCT01460134 Completed Celldex Therapeutics 2015-12-31
NCT01457144 Study of Mantle Cell Lymphoma Treatment by RiBVD https://ClinicalTrials.gov/show/NCT01457144 Completed French Innovative Leukemia Organisation 2014-09-30
NCT01456351 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab https://ClinicalTrials.gov/show/NCT01456351 Completed University of Giessen 2010-08-31
NCT01439750 Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) https://ClinicalTrials.gov/show/NCT01439750 Active, not recruiting Milton S. Hershey Medical Center 2018-08-31
NCT01437709 Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01437709 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-09-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01415752 Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01415752 Active, not recruiting Eastern Cooperative Oncology Group 2020-03-31
NCT01412879 S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01412879 Active, not recruiting Southwest Oncology Group 2016-02-29
NCT01410513 Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01410513 Completed Sanofi 2014-05-31
NCT01399840 Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT01399840 Completed Pfizer 2014-03-31
NCT01397825 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine https://ClinicalTrials.gov/show/NCT01397825 Completed Takeda 2015-02-05
NCT01389427 Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL). https://ClinicalTrials.gov/show/NCT01389427 Completed The Lymphoma Academic Research Organisation 2015-05-31
NCT01345357 Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01345357 Completed Teva Pharmaceutical Industries 2012-12-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04323657 TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia https://ClinicalTrials.gov/show/NCT04323657 Recruiting TCR2 Therapeutics 2022-04-30
NCT04282018 Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab https://ClinicalTrials.gov/show/NCT04282018 Recruiting BeiGene 2025-03-26
NCT04231734 Ketogenic Diet in Patients With Untreated Low Tumor Burden Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04231734 Recruiting Weill Medical College of Cornell University 2021-12-31
NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04191187 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-12-31
NCT04186520 CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies https://ClinicalTrials.gov/show/NCT04186520 Recruiting Medical College of Wisconsin 2023-05-01
NCT04184414 The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies https://ClinicalTrials.gov/show/NCT04184414 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2020-01-01
NCT04176913 Study of LUCAR-20S in Patients With R/R NHL https://ClinicalTrials.gov/show/NCT04176913 Recruiting The First Affiliated Hospital with Nanjing Medical University 2022-10-22
NCT04115631 A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04115631 Recruiting Eastern Cooperative Oncology Group 2024-03-31
NCT04082936 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04082936 Recruiting IGM Biosciences, Inc. 2021-09-30
NCT04054167 Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04054167 Recruiting M.D. Anderson Cancer Center 2021-05-29
NCT04049513 ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) https://ClinicalTrials.gov/show/NCT04049513 Recruiting Malaghan Institute of Medical Research 2021-09-30
NCT04047797 Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04047797 Recruiting M.D. Anderson Cancer Center 2022-06-01
NCT04014205 A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies https://ClinicalTrials.gov/show/NCT04014205 Recruiting Beijing InnoCare Pharma Tech Co., Ltd. 2020-08-17
NCT04007029 Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT04007029 Recruiting Jonsson Comprehensive Cancer Center 2022-08-01
NCT04002297 Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04002297 Recruiting BeiGene 2021-07-31
NCT03999697 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies https://ClinicalTrials.gov/show/NCT03999697 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2020-12-01
NCT03997968 A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT03997968 Recruiting Cyteir Therapeutics, Inc. 2021-09-30
NCT03946878 Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03946878 Recruiting M.D. Anderson Cancer Center 2024-02-08
NCT03939182 Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03939182 Recruiting Memorial Sloan Kettering Cancer Center 2021-05-31
NCT03891355 Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL https://ClinicalTrials.gov/show/NCT03891355 Recruiting Fondazione Italiana Linfomi ONLUS 2020-04-30
NCT03886831 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03886831 Recruiting Prelude Therapeutics 2021-08-11
NCT03877055 A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03877055 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT03863184 Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL https://ClinicalTrials.gov/show/NCT03863184 Recruiting Weill Medical College of Cornell University 2022-11-01
NCT03842696 Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation https://ClinicalTrials.gov/show/NCT03842696 Recruiting University of Michigan Rogel Cancer Center 2024-02-29
NCT03836768 BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03836768 Active, not recruiting Zhejiang DTRM Biopharma 2021-09-30
NCT03834688 Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age https://ClinicalTrials.gov/show/NCT03834688 Recruiting PrECOG, LLC. 2022-03-31
NCT03833180 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03833180 Recruiting VelosBio Inc. 2021-03-31
NCT03740529 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL https://ClinicalTrials.gov/show/NCT03740529 Recruiting Loxo Oncology, Inc. 2020-10-31
NCT03710772 Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03710772 Recruiting M.D. Anderson Cancer Center 2021-04-22
NCT03685344 Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03685344 Active, not recruiting ADC Therapeutics S.A. 2021-01-29
NCT03684694 Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03684694 Recruiting ADC Therapeutics S.A. 2022-04-15
NCT03676504 Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR https://ClinicalTrials.gov/show/NCT03676504 Recruiting University Hospital Heidelberg 2020-03-01
NCT03674411 Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy https://ClinicalTrials.gov/show/NCT03674411 Recruiting Masonic Cancer Center, University of Minnesota 2023-07-31
NCT03629873 Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects https://ClinicalTrials.gov/show/NCT03629873 Recruiting The First Affiliated Hospital with Nanjing Medical University 2019-08-01
NCT03625037 GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03625037 Recruiting Genmab 2022-01-30
NCT03623373 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03623373 Active, not recruiting Washington University School of Medicine 2020-02-09
NCT03622788 Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03622788 Recruiting M.D. Anderson Cancer Center 2021-07-01
NCT03601819 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT03601819 Recruiting University of Michigan Rogel Cancer Center 2021-09-30
NCT03585725 A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03585725 Recruiting Weill Medical College of Cornell University 2020-06-30
NCT03571828 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT03571828 Recruiting Amgen 2023-06-30
NCT03567876 Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL https://ClinicalTrials.gov/show/NCT03567876 Recruiting Fondazione Italiana Linfomi ONLUS 2020-07-31
NCT03547115 A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML https://ClinicalTrials.gov/show/NCT03547115 Recruiting MEI Pharma, Inc. 2022-04-30
NCT03505944 Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03505944 Recruiting Nordic Lymphoma Group 2020-12-01
NCT03501576 Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma https://ClinicalTrials.gov/show/NCT03501576 Recruiting Emory University 2021-04-30
NCT03494179 A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT03494179 Active, not recruiting Beijing InnoCare Pharma Tech Co., Ltd. 2020-06-30
NCT03478514 Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03478514 Recruiting Alliance Foundation Trials, LLC. 2022-06-30
NCT03440567 Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03440567 Recruiting City of Hope Medical Center 2021-04-02
NCT03424603 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies https://ClinicalTrials.gov/show/NCT03424603 Recruiting Sutro Biopharma, Inc. 2021-11-30
NCT01267812 Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT01267812 Active, not recruiting City of Hope Medical Center 2018-09-07
NCT01263899 A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01263899 Completed S*BIO 2012-02-29
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01251575 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01251575 Completed Fred Hutchinson Cancer Research Center 2018-11-23
NCT01239875 Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01239875 Completed Mayo Clinic 2015-11-24
NCT01236391 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT01236391 Completed Pharmacyclics LLC. 2014-01-31
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01231412 Completed Fred Hutchinson Cancer Research Center 2016-10-08
NCT01184885 A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy https://ClinicalTrials.gov/show/NCT01184885 Completed Thomas Jefferson University 2011-03-31
NCT01181271 Tandem Auto-Allo Transplant for Lymphoma https://ClinicalTrials.gov/show/NCT01181271 Completed Massachusetts General Hospital 2014-02-28
NCT01180049 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01180049 Completed Pfizer 2015-11-30
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT03872180 Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03872180 Recruiting Emory University 2021-04-30
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01148108 Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma https://ClinicalTrials.gov/show/NCT01148108 Completed Telik 2012-09-30
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01118845 Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01118845 Completed SymBio Pharmaceuticals 2011-10-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01109069 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01109069 Completed Pharmacyclics LLC. 2019-04-26
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01088048 Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01088048 Completed Gilead Sciences 2015-04-30
NCT01078142 Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT01078142 Completed Johannes Gutenberg University Mainz 2017-09-08
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01073163 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT01073163 Completed Teva Pharmaceutical Industries 2012-06-30
NCT01053494 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer https://ClinicalTrials.gov/show/NCT01053494 Completed Wake Forest University Health Sciences 2012-02-29
NCT01035463 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy https://ClinicalTrials.gov/show/NCT01035463 Completed University of Nebraska 2017-07-27
NCT01029366 CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy https://ClinicalTrials.gov/show/NCT01029366 Completed University of Pennsylvania 2015-07-31
NCT00992992 Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00992992 Completed GlaxoSmithKline 2013-06-30
NCT00992446 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00992446 Completed Fred Hutchinson Cancer Research Center 2015-06-17
NCT00992134 Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00992134 Completed St. Bortolo Hospital 2011-06-30
NCT00980395 Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma https://ClinicalTrials.gov/show/NCT00980395 Completed University of Arizona 2014-09-12
NCT00963534 Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. https://ClinicalTrials.gov/show/NCT00963534 Completed Lund University Hospital 2017-08-31
NCT00958256 Study of Bortezomib in Combination With Cyclophosphamide and Rituximab https://ClinicalTrials.gov/show/NCT00958256 Completed M.D. Anderson Cancer Center 2014-03-31
NCT00921414 Mantel Cell Lymphoma Efficacy of Rituximab Maintenance https://ClinicalTrials.gov/show/NCT00921414 Completed French Innovative Leukemia Organisation 2008-09-30
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00901615 Lenalidomide and R-CHOP in B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00901615 Completed Lymphoma Study Association 2010-11-19
NCT00891839 Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00891839 Completed Teva Pharmaceutical Industries 2011-12-31
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00880815 Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00880815 Completed M.D. Anderson Cancer Center 2019-05-28
NCT00878254 Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00878254 Active, not recruiting University of Miami 2021-09-30
NCT00877214 Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT00877214 Active, not recruiting University of Giessen 2022-04-30
NCT00877006 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study https://ClinicalTrials.gov/show/NCT00877006 Completed Teva Pharmaceutical Industries 2012-03-31
NCT00875667 A Study to Determine the Efficacy of Lenalidomide Versus Investigator’s Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT00875667 Completed Celgene 2018-06-28
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00861510 A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00861510 Completed National Institutes of Health Clinical Center (CC) 2012-10-19
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00807495 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00807495 Completed Takeda 2011-01-04
NCT01686165 Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL https://ClinicalTrials.gov/show/NCT01686165 Completed University of Arizona 2016-02-09
NCT01474681 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01474681 Completed Novartis 2016-10-03
NCT03523975 Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03523975 Recruiting University of Michigan Rogel Cancer Center 2020-07-31
NCT03682796 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT03682796 Recruiting Triphase Research and Development III Corp. 2022-01-31
NCT03185494 Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 https://ClinicalTrials.gov/show/NCT03185494 Active, not recruiting Chinese PLA General Hospital 2019-08-01
NCT03147885 Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03147885 Recruiting Barbara Ann Karmanos Cancer Institute 2020-06-30
NCT03061188 Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes https://ClinicalTrials.gov/show/NCT03061188 Active, not recruiting Northwestern University 2020-09-30
NCT02601313 A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02601313 Active, not recruiting Gilead Sciences 2019-07-24
NCT03616782 Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) https://ClinicalTrials.gov/show/NCT03616782 Recruiting Kosin University Gospel Hospital 2022-12-31
NCT00875056 Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin’s Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients (MK-0683-103) https://ClinicalTrials.gov/show/NCT00875056 Completed Merck Sharp & Dohme Corp. 2011-02-25
NCT00794638 A Phase I Clinical Trial to Assess the Safety of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00794638 Completed SymBio Pharmaceuticals 2010-03-31
NCT00791011 Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat https://ClinicalTrials.gov/show/NCT00791011 Completed Amgen 2010-07-31
NCT00789776 Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00789776 Completed Fred Hutchinson Cancer Research Center 2017-05-31
NCT00787969 Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00787969 Completed Alliance for Clinical Trials in Oncology 2012-04-30
NCT00786851 Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT00786851 Completed Fondazione Italiana Linfomi ONLUS 2010-07-31
NCT00783367 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00783367 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2012-11-14
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00764517 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00764517 Completed OHSU Knight Cancer Institute 2015-01-31
NCT00740415 Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00740415 Completed French Innovative Leukemia Organisation 2011-05-31
NCT00737529 A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The “EMERGE” Trial https://ClinicalTrials.gov/show/NCT00737529 Completed Celgene 2016-04-06
NCT00723099 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00723099 Completed Fred Hutchinson Cancer Research Center 2018-07-31
NCT00722137 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00722137 Completed Takeda 2014-01-01
NCT00719888 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease https://ClinicalTrials.gov/show/NCT00719888 Recruiting Fred Hutchinson Cancer Research Center 2022-12-31
NCT00711828 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00711828 Completed Mayo Clinic 2013-11-30
NCT00703664 Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00703664 Completed National Cancer Institute (NCI) 2017-12-01
NCT00702052 Safety and Efficacy of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy. https://ClinicalTrials.gov/show/NCT00702052 Completed Novartis 2012-04-30
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00656084 Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell https://ClinicalTrials.gov/show/NCT00656084 Completed US Oncology Research 2007-01-31
NCT00644189 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00644189 Active, not recruiting Massachusetts General Hospital 2013-12-31
NCT00641095 Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00641095 Completed University College, London 2011-11-23
NCT00633594 Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00633594 Completed SCRI Development Innovations, LLC 2015-04-30
NCT00621452 Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00621452 Completed Fred Hutchinson Cancer Research Center 2014-01-31
NCT00612183 Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00612183 Completed SymBio Pharmaceuticals 2009-09-30
NCT00609869 Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab https://ClinicalTrials.gov/show/NCT00609869 Completed H. Lee Moffitt Cancer Center and Research Institute 2014-02-28
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00607854 Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) https://ClinicalTrials.gov/show/NCT00607854 Completed University Hospital, Bordeaux 2011-02-28
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00586755 Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00586755 Completed Duke University 2007-10-31
NCT00581854 Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00581854 Completed University of Wisconsin, Madison 2006-06-30
NCT00581776 Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00581776 Completed University of Wisconsin, Madison 2012-11-30
NCT00571493 VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin’s Lymphoma, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00571493 Completed University of Nebraska 2014-11-30
NCT00553644 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00553644 Completed National Cancer Institute (NCI) 2012-12-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00516412 Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00516412 Completed Swiss Group for Clinical Cancer Research 2010-01-31
NCT00514475 Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00514475 Completed Oslo University Hospital 2009-06-30
NCT00513955 Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00513955 Completed University Hospital Plymouth NHS Trust 2014-10-31
NCT00505232 Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) https://ClinicalTrials.gov/show/NCT00505232 Completed CABYC 2010-03-31
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00490529 Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL https://ClinicalTrials.gov/show/NCT00490529 Completed Stanford University 2017-12-14
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00477412 Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00477412 Active, not recruiting M.D. Anderson Cancer Center 2021-04-30
NCT00472420 A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. https://ClinicalTrials.gov/show/NCT00472420 Completed Hoffmann-La Roche 2011-05-25
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00446342 Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00446342 Completed Sunesis Pharmaceuticals 2008-12-31
NCT00445341 Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00445341 Completed National Institutes of Health Clinical Center (CC) 2012-04-30
NCT00438880 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00438880 Completed Mayo Clinic 2010-10-31
NCT00433537 Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00433537 Completed National Cancer Institute (NCI) 2013-06-30
NCT00420056 An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma. https://ClinicalTrials.gov/show/NCT00420056 Completed Pfizer 2010-03-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00407303 Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT00407303 Completed Teva Pharmaceutical Industries 2009-03-31
NCT00406809 A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00406809 Completed AbbVie 2016-10-31
NCT00401817 Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00401817 Completed Weill Medical College of Cornell University 2011-07-31
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00377052 Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00377052 Completed Canadian Cancer Trials Group 2009-04-21
NCT00376961 S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00376961 Completed Southwest Oncology Group 2012-12-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00310037 Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00310037 Active, not recruiting Alliance for Clinical Trials in Oncology 2013-12-31
NCT00294632 Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00294632 Completed M.D. Anderson Cancer Center 2016-02-29
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00285389 Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years https://ClinicalTrials.gov/show/NCT00285389 Completed French Innovative Leukemia Organisation 2005-12-31
NCT00278382 Sorafenib in Treating Patients With Recurrent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00278382 Completed National Cancer Institute (NCI) 2007-12-31
NCT00275431 Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies https://ClinicalTrials.gov/show/NCT00275431 Completed Ascenta Therapeutics 2008-12-31
NCT00275080 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00275080 Completed National Cancer Institute (NCI) 2009-11-30
NCT00253630 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00253630 Completed National Cancer Institute (NCI) 2016-05-31
NCT00234026 Gemcitabine in Treating Patients With Newly Diagnosed, Relapsed, or Chemotherapy-Resistant Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00234026 Completed Swiss Group for Clinical Cancer Research 2006-03-31
NCT00225212 Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00225212 Completed Stanford University 2003-03-31
NCT02840539 Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02840539 Recruiting Seoul National University Hospital 2020-02-29
NCT00201877 Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00201877 Completed Ohio State University Comprehensive Cancer Center 2009-06-30
NCT00186628 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD https://ClinicalTrials.gov/show/NCT00186628 Completed Stanford University 2010-11-30
NCT00151281 Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00151281 Completed Weill Medical College of Cornell University 2009-12-31
NCT00119730 Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00119730 Completed Dana-Farber Cancer Institute 2006-12-31
NCT00119392 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00119392 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00118170 Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function https://ClinicalTrials.gov/show/NCT00118170 Completed National Cancer Institute (NCI) 2007-05-31
NCT00117988 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00117988 Completed National Cancer Institute (NCI) 2010-04-30
NCT00117598 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) https://ClinicalTrials.gov/show/NCT00117598 Completed Pfizer 2007-08-31
NCT00114738 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00114738 Active, not recruiting National Institutes of Health Clinical Center (CC) 2016-08-11
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00110071 Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00110071 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00109967 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00109967 Completed National Cancer Institute (NCI) 2009-09-30
NCT00109824 Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00109824 Completed National Cancer Institute (NCI) 2009-03-31
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00003039 Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin’s Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00003039 Completed National Cancer Institute (NCI) 2000-04-30
NCT00090090 Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00090090 Completed Spectrum Pharmaceuticals, Inc NA
NCT00002879 Cladribine in Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00002879 Completed Alliance for Clinical Trials in Oncology 2005-04-30
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00086944 Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00086944 Completed National Cancer Institute (NCI) 2006-07-31
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00082784 Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms https://ClinicalTrials.gov/show/NCT00082784 Completed National Cancer Institute (NCI) 2012-10-31
NCT00081874 RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00081874 Completed M.D. Anderson Cancer Center 2006-09-30
NCT00003166 Bryostatin and Vincristine in B-Cell Malignancies https://ClinicalTrials.gov/show/NCT00003166 Completed National Cancer Institute (NCI) 2001-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00003541 Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00003541 Completed Memorial Sloan Kettering Cancer Center 2006-07-31
NCT00075478 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00075478 Completed Fred Hutchinson Cancer Research Center 2014-02-28
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00070447 Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00070447 Completed National Cancer Institute (NCI) NA
NCT00003280 Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00003280 Completed Swiss Group for Clinical Cancer Research 2002-03-31
NCT00068315 Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00068315 Completed National Cancer Institute (NCI) 2008-12-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00063713 VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00063713 Completed Millennium Pharmaceuticals, Inc. 2005-12-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00060372 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer https://ClinicalTrials.gov/show/NCT00060372 Completed National Cancer Institute (NCI) 2008-04-30
NCT00003311 Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00003311 Completed M.D. Anderson Cancer Center 2007-04-18
NCT00058305 Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00058305 Completed National Cancer Institute (NCI) 2007-12-31
NCT00058227 Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00058227 Completed National Cancer Institute (NCI) 2009-02-28
NCT00058019 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00058019 Completed National Cancer Institute (NCI) 2010-08-31
NCT00054639 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00054639 Completed National Cancer Institute (NCI) 2010-01-31
NCT00054483 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00054483 Completed National Cancer Institute (NCI) 2009-09-30
NCT00053092 Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00053092 Completed National Cancer Institute (NCI) NA
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00041132 S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00041132 Completed Southwest Oncology Group 2007-11-30
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00033267 CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00033267 Completed National Cancer Institute (NCI) 2006-02-28
NCT00030875 Bortezomib in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00030875 Completed Canadian Cancer Trials Group 2005-07-21
NCT00026182 Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00026182 Completed National Cancer Institute (NCI) 2005-02-28
NCT00025662 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS https://ClinicalTrials.gov/show/NCT00025662 Completed National Institutes of Health Clinical Center (CC) 2008-02-29
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00020943 Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00020943 Completed Alliance for Clinical Trials in Oncology 2006-12-31
NCT00017381 Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00017381 Completed National Cancer Institute (NCI) 2007-12-31
NCT00016094 S0108 Bevacizumab in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00016094 Completed National Cancer Institute (NCI) 2005-08-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00010192 Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00010192 Completed National Cancer Institute (NCI) 2003-01-31
NCT00006747 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00006747 Completed Alliance for Clinical Trials in Oncology 2003-02-28
NCT00006473 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006473 Completed National Cancer Institute (NCI) 2006-02-28
NCT00005074 Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00005074 Completed Canadian Cancer Trials Group 2002-02-20
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00004231 Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00004231 Completed Northwestern University 2006-08-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31
NCT00038623 Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00038623 Completed M.D. Anderson Cancer Center 2007-12-31
NCT00450801 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00450801 Completed University of Miami 2015-07-31
NCT00022945 Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00022945 Completed Corixa Corporation NA
NCT00023764 Bortezomib in Treating Patients With Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00023764 Completed National Cancer Institute (NCI) 2009-03-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03816683 A Disease Registry of Patients With Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT03816683 Recruiting AstraZeneca 2024-04-30
NCT03054883 Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy https://ClinicalTrials.gov/show/NCT03054883 Completed Czech Lymphoma Study Group 2015-12-31
NCT03053024 Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants https://ClinicalTrials.gov/show/NCT03053024 Completed Xian-Janssen Pharmaceutical Ltd. 2019-09-30
NCT02341781 Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment https://ClinicalTrials.gov/show/NCT02341781 Completed Celgene 2016-09-30
NCT01367457 INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus https://ClinicalTrials.gov/show/NCT01367457 Completed Pfizer 2015-04-30
NCT04407845 Atrial Fibrillation in Patients Receiving Ibrutinib https://ClinicalTrials.gov/show/NCT04407845 Recruiting European Georges Pompidou Hospital 2022-05-21
NCT04109872 Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results. https://ClinicalTrials.gov/show/NCT04109872 Recruiting Fundación Pública Andaluza para la gestión de la Investigación en Sevilla 2020-06-15
NCT04061850 Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT04061850 Recruiting Samsung Medical Center 2020-06-30
NCT03647124 Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden https://ClinicalTrials.gov/show/NCT03647124 Recruiting Celgene 2026-12-31
NCT03476655 Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India https://ClinicalTrials.gov/show/NCT03476655 Completed Johnson & Johnson Private Limited 2019-05-14
NCT03425591 A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT03425591 Recruiting Janssen-Cilag Ltd. 2022-05-22
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01117142 A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy Volunteers https://ClinicalTrials.gov/show/NCT01117142 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT00700258 Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] https://ClinicalTrials.gov/show/NCT00700258 Recruiting Pfizer 2023-12-01

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03869619 REal World Data in LYmphoma and Survival in Adults https://ClinicalTrials.gov/show/NCT03869619 Recruiting Hospices Civils de Lyon 2027-10-31
NCT04127916 Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL) https://ClinicalTrials.gov/show/NCT04127916 Recruiting Samsung Medical Center 2020-12-31